Exact Mass: 387.2481568
Exact Mass Matches: 387.2481568
Found 500 metabolites which its exact mass value is equals to given mass value 387.2481568,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4-Hydroxytamoxifen
4-Hydroxytamoxifen (Afimoxifene) is a metabolite of Tamoxifen. Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. (Wikipedia) D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
3-Hydroxytamoxifen (Droloxifene)
3-Hydroxytamoxifen (Droloxifene) is only found in individuals that have used or taken Tamoxifen. 3-Hydroxytamoxifen (Droloxifene) is a metabolite of Tamoxifen. 3-hydroxytamoxifen (droloxifene) belongs to the family of Stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Same as: D03911
alpha-Hydroxytamoxifen
alpha-Hydroxytamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
Tamoxifen N-oxide
Tamoxifen N-oxide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
3-Hydroxydodec-6-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxydodec-9-enedioylcarnitine
C19H33NO7 (387.22569080000005)
10-Hydroxydodec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxydodec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodec-9-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodec-9-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydodec-5-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E)-3-Hydroxydodec-4-enedioylcarnitine
C19H33NO7 (387.22569080000005)
(4E)-3-Hydroxydodec-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an (4E)-3-hydroxydodec-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-3-Hydroxydodec-4-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-3-Hydroxydodec-4-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydodec-9-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-9-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-9-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydodec-8-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-8-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-8-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-8-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-8-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxydodec-10-enedioylcarnitine
C19H33NO7 (387.22569080000005)
10-Hydroxydodec-10-enedioylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxydodec-10-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodec-10-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodec-10-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydodec-10-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-10-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-10-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-10-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-10-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxydodec-7-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-7-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-7-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-7-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-7-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tridecanedioylcarnitine
C20H37NO6 (387.26207420000003)
Tridecanedioylcarnitine is an acylcarnitine. More specifically, it is an tridecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Palmitoyl Methionine
C21H41NO3S (387.28069960000005)
N-palmitoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Stearoyl Cysteine
C21H41NO3S (387.28069960000005)
N-stearoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Fingolimod phosphate ester, S-
C19H34NO5P (387.2174484000001)
[1S-[1alpha,2alpha(Z),3alpha,4alpha]]-7-[3-[[2-[(Phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoicacid
C21H29N3O4 (387.21579540000005)
trimebutine
C22H29NO5 (387.20456240000004)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D005765 - Gastrointestinal Agents Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects. Target: Opioid Receptor Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3].
urapidil
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist.
urapidil
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist.
trimebutine
C22H29NO5 (387.20456240000004)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D005765 - Gastrointestinal Agents Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects. Target: Opioid Receptor Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3].
(4SR,4aRS,8RS,8aRS,11aRS,11bRS)-1,2,3,4,4a,5,8,8a,9,11a-decahydro-11a-hydroxy-2-methyl-4a-(4-methyl-3-oxopentyl)-7H-4,11-ethano-8,11b-methanocyclopenta[5,6]oxocino[4,3-c]pyridin-7-one|daphnilongertone
21-O-acetylpaxdaphnine B|methyl (2R,5S,8S,15R)-2-(acetoxymethyl)-5-ethyl-6-azapentacyclo[9.5.1.01,5.02,8.014,17]heptadec-11(17)-ene-15-carboxylate
methyl 4-[(E)-2-acetyl-4-oxoundec-1-enyl]-6-propylnicotinate
2-(12-Hydroxy-12-methyltridecyl)-3-methoxyquinolin-4(1H)-one
C24H37NO3 (387.27732920000005)
7-[3-[[[anilino(oxo)methyl]hydrazo]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoic acid
C21H29N3O4 (387.21579540000005)
Ala Ala Ala Arg
C15H29N7O5 (387.22300640000003)
Ala Ala Ile Asn
Ala Ala Lys Val
Ala Ala Leu Asn
Ala Ala Asn Ile
Ala Ala Asn Leu
Ala Ala Gln Val
Ala Ala Arg Ala
C15H29N7O5 (387.22300640000003)
Ala Ala Val Lys
Ala Ala Val Gln
Ala Gly Ile Lys
Ala Gly Ile Gln
Ala Gly Lys Ile
Ala Gly Lys Leu
Ala Gly Leu Lys
Ala Gly Leu Gln
Ala Gly Gln Ile
Ala Gly Gln Leu
Ala Ile Ala Asn
Ala Ile Gly Lys
Ala Ile Gly Gln
Ala Ile Lys Gly
Ala Ile Asn Ala
Ala Ile Gln Gly
Ala Lys Ala Val
Ala Lys Gly Ile
Ala Lys Gly Leu
Ala Lys Ile Gly
Ala Lys Leu Gly
Ala Lys Val Ala
Ala Leu Ala Asn
Ala Leu Gly Lys
Ala Leu Gly Gln
Ala Leu Lys Gly
Ala Leu Asn Ala
Ala Leu Gln Gly
Ala Asn Ala Ile
Ala Asn Ala Leu
Ala Asn Ile Ala
Ala Asn Leu Ala
Ala Gln Ala Val
Ala Gln Gly Ile
Ala Gln Gly Leu
Ala Gln Ile Gly
Ala Gln Leu Gly
Ala Gln Val Ala
Ala Arg Ala Ala
C15H29N7O5 (387.22300640000003)
Ala Val Ala Lys
Ala Val Ala Gln
Ala Val Lys Ala
Ala Val Gln Ala
Gly Ala Ile Lys
Gly Ala Ile Gln
Gly Ala Lys Ile
Gly Ala Lys Leu
Gly Ala Leu Lys
Gly Ala Leu Gln
Gly Ala Gln Ile
Gly Ala Gln Leu
Gly Gly Arg Val
C15H29N7O5 (387.22300640000003)
Gly Gly Val Arg
C15H29N7O5 (387.22300640000003)
Gly Ile Ala Lys
Gly Ile Ala Gln
Gly Ile Lys Ala
Gly Ile Gln Ala
Gly Lys Ala Ile
Gly Lys Ala Leu
Gly Lys Ile Ala
Gly Lys Leu Ala
Gly Lys Pro Ser
Gly Lys Ser Pro
Gly Leu Ala Lys
Gly Leu Ala Gln
Gly Leu Lys Ala
Gly Leu Gln Ala
Gly Asn Val Val
Gly Pro Lys Ser
Gly Pro Ser Lys
Gly Gln Ala Ile
Gly Gln Ala Leu
Gly Gln Ile Ala
Gly Gln Leu Ala
Gly Arg Gly Val
C15H29N7O5 (387.22300640000003)
Gly Arg Val Gly
C15H29N7O5 (387.22300640000003)
Gly Ser Lys Pro
Gly Ser Pro Lys
Gly Val Gly Arg
C15H29N7O5 (387.22300640000003)
Gly Val Asn Val
Gly Val Arg Gly
C15H29N7O5 (387.22300640000003)
Gly Val Val Asn
Ile Ala Ala Asn
Ile Ala Gly Lys
Ile Ala Gly Gln
Ile Ala Lys Gly
Ile Ala Asn Ala
Ile Ala Gln Gly
Ile Gly Ala Lys
Ile Gly Ala Gln
Ile Gly Lys Ala
Ile Gly Gln Ala
Ile Lys Ala Gly
Ile Lys Gly Ala
Ile Asn Ala Ala
Ile Gln Ala Gly
Ile Gln Gly Ala
Lys Ala Ala Val
Lys Ala Gly Ile
Lys Ala Gly Leu
Lys Ala Ile Gly
Lys Ala Leu Gly
Lys Ala Val Ala
Lys Gly Ala Ile
Lys Gly Ala Leu
Lys Gly Ile Ala
Lys Gly Leu Ala
Lys Gly Pro Ser
Lys Gly Ser Pro
Lys Ile Ala Gly
Lys Ile Gly Ala
Lys Leu Ala Gly
Lys Leu Gly Ala
Lys Pro Gly Ser
Lys Pro Ser Gly
Lys Ser Gly Pro
Lys Ser Pro Gly
Lys Val Ala Ala
Leu Ala Ala Asn
Leu Ala Gly Lys
Leu Ala Gly Gln
Leu Ala Lys Gly
Leu Ala Asn Ala
Leu Ala Gln Gly
Leu Gly Ala Lys
Leu Gly Ala Gln
Leu Gly Lys Ala
Leu Gly Gln Ala
Leu Lys Ala Gly
Leu Lys Gly Ala
Leu Asn Ala Ala
Leu Gln Ala Gly
Leu Gln Gly Ala
Asn Ala Ala Ile
Asn Ala Ala Leu
Asn Ala Ile Ala
Asn Ala Leu Ala
Asn Gly Val Val
Asn Ile Ala Ala
Asn Leu Ala Ala
Asn Val Gly Val
Asn Val Val Gly
Pro Gly Lys Ser
Pro Gly Ser Lys
Pro Lys Gly Ser
Pro Lys Ser Gly
Pro Ser Gly Lys
Pro Ser Lys Gly
Gln Ala Ala Val
Gln Ala Gly Ile
Gln Ala Gly Leu
Gln Ala Ile Gly
Gln Ala Leu Gly
Gln Ala Val Ala
Gln Gly Ala Ile
Gln Gly Ala Leu
Gln Gly Ile Ala
Gln Gly Leu Ala
Gln Ile Ala Gly
Gln Ile Gly Ala
Gln Leu Ala Gly
Gln Leu Gly Ala
Gln Val Ala Ala
Arg Ala Ala Ala
C15H29N7O5 (387.22300640000003)
Arg Gly Gly Val
C15H29N7O5 (387.22300640000003)
Arg Gly Val Gly
C15H29N7O5 (387.22300640000003)
Arg Val Gly Gly
C15H29N7O5 (387.22300640000003)
Ser Gly Lys Pro
Ser Gly Pro Lys
Ser Lys Gly Pro
Ser Lys Pro Gly
Ser Pro Gly Lys
Ser Pro Lys Gly
Val Ala Ala Lys
Val Ala Ala Gln
Val Ala Lys Ala
Val Ala Gln Ala
Val Gly Gly Arg
C15H29N7O5 (387.22300640000003)
Val Gly Asn Val
Val Gly Arg Gly
C15H29N7O5 (387.22300640000003)
Val Gly Val Asn
Val Lys Ala Ala
Val Asn Gly Val
Val Asn Val Gly
Val Gln Ala Ala
Val Arg Gly Gly
C15H29N7O5 (387.22300640000003)
Val Val Gly Asn
Val Val Asn Gly
FTY720 (R)-Phosphate
C19H34NO5P (387.2174484000001)
(S) FTY720 Phosphate
C19H34NO5P (387.2174484000001)
FTY720 phosphate
C19H34NO5P (387.2174484000001)
17-phenyl-trinor-PGF2alpha amide
13-HDHEA
C24H37NO3 (387.27732920000005)
16-HDHEA
C24H37NO3 (387.27732920000005)
tris(2-hydroxyethyl)ammonium decyl sulphate
C16H37NO7S (387.22906120000005)
hexyl 6-aminohexanoate,4-methylbenzenesulfonic acid
C19H33NO5S (387.2079328000001)
4-Hydroxy-alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
Nufenoxole
C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent
4-(3-ethoxycarbonylpiperidine)carboxamidophenylboronic acid, pinacol ester
dimethyl hydrogen phosphorate, compound with 4-tetrapropyleneaniline
C20H38NO4P (387.25383180000006)
2-aminoethanol,2-dodecylbenzenesulfonic acid
C20H37NO4S (387.24431620000007)
1H-Benzimidazole,2-[1-[[1-(2-phenylethyl)-1H-tetrazol-5-yl]methyl]-4-piperidinyl]-(9CI)
(E)-4-HYDROXYTAMOXIFEN
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists D000970 - Antineoplastic Agents
6-[benzenesulfonyl(methyl)amino]hexanoic acid,N,N-dimethylpropane-1,3-diamine
C18H33N3O4S (387.21916580000004)
4-(1-(1-ethoxyethyl)-1h-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7h-pyrrolo(2,3-d)pyrimidine
β-Methyl-γ-decalactone, mixt. with Phenylephrine hydrochloride (1:1)
C20H34ClNO4 (387.2176234000001)
Ethyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperidine-3-carboxylate
Barbexaclone
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AA - Barbiturates and derivatives C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
4-[(1E)-1-{4-[2-(Dimethylamino)ethoxy]phenyl}-1-phenylbut-1-en-2-yl]phenol
Progesterone 3-carboxymethyloxime
Droloxifene
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Same as: D03911
3,4-dihydro-1H-isoquinolin-2-yl-[1-(6-pyrrol-1-ylpyrimidin-4-yl)piperidin-4-yl]methanone
7alpha-Hydroxy-3-oxochol-4-en-24-Oate
C24H35O4- (387.25352100000003)
A bile acid anion that is the conjugate base of 7alpha-hydroxy-3-oxochol-4-en-24-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(E)-7-[3-[[2-(phenylcarbamoyl)hydrazinyl]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
C21H29N3O4 (387.21579540000005)
2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine oxide
3-Hydroxydodec-6-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-5-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-9-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-8-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-7-enedioylcarnitine
C19H33NO7 (387.22569080000005)
10-Hydroxydodec-9-enedioylcarnitine
C19H33NO7 (387.22569080000005)
3-Hydroxydodec-10-enedioylcarnitine
C19H33NO7 (387.22569080000005)
10-Hydroxydodec-10-enedioylcarnitine
C19H33NO7 (387.22569080000005)
(4E)-3-Hydroxydodec-4-enedioylcarnitine
C19H33NO7 (387.22569080000005)
(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]hexanoic acid
C18H37N5O4 (387.28454020000004)
N-[3-(1-azepanyl)propyl]-1-[(4-methoxyphenyl)methyl]-5-oxo-3-pyrrolidinecarboxamide
N-[2-[1-[(E)-3-phenylprop-2-enyl]benzimidazol-2-yl]ethyl]cyclohexanecarboxamide
N-ethyl-N-[[(2S,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
N-ethyl-N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
1-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-cyclopentyl-3-propan-2-ylurea
(2S,3S,4R)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
C21H29N3O4 (387.21579540000005)
1-[(2S,3S)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-1-oxoethyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]-1-propanone
C21H29N3O4 (387.21579540000005)
(2R,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C21H29N3O4 (387.21579540000005)
N-ethyl-N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
1-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-cyclopentyl-3-propan-2-ylurea
(2R,3S,4S)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
(2S,3R,4R)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
(2R,3R,4S)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
C21H29N3O4 (387.21579540000005)
(2S,3S)-N-cyclopentyl-2-(hydroxymethyl)-6-(2-methoxy-1-oxoethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C21H29N3O4 (387.21579540000005)
(2S,3R)-N-cyclopentyl-2-(hydroxymethyl)-6-(2-methoxy-1-oxoethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C21H29N3O4 (387.21579540000005)
1-[(2R,3R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-1-oxoethyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]-1-propanone
C21H29N3O4 (387.21579540000005)
(2R,3R)-N-cyclopentyl-2-(hydroxymethyl)-6-(2-methoxy-1-oxoethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C21H29N3O4 (387.21579540000005)
[(2S,3R)-3-phenyl-6-(2-pyridinylmethyl)-1-(5-pyrimidinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
[(2R,3R)-3-phenyl-6-(2-pyridinylmethyl)-1-(5-pyrimidinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
2-(dimethylamino)-1-[(2S,3R)-2-(hydroxymethyl)-6-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
1-[(2S,3R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-1-oxoethyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]-1-propanone
C21H29N3O4 (387.21579540000005)
15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadecanoate
(14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxypentadecanoate
14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoate
(13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoate
Afimoxifene
A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
Tamoxifen N-oxide
A tertiary amine oxide resulting from the formal oxidation of the amino group of tamoxifen.
oscr#26(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#26, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2,2,2-trifluoro-1-{2-methyl-3-[(7z)-pentadec-7-en-1-yl]-4,5-dihydropyrrol-1-yl}ethanone
C22H36F3NO (387.27488420000003)
methyl (1r,2r,5s,8s,14r,15r)-2-[(acetyloxy)methyl]-5-ethyl-6-azapentacyclo[9.5.1.0¹,⁵.0²,⁸.0¹⁴,¹⁷]heptadec-11(17)-ene-15-carboxylate
(2e,4e,6z,8e,10e,12s,13r,14e)-13-hydroxy-n-[(2r)-1-hydroxypropan-2-yl]-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
n-(6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl)ethanimidic acid
(2e,4e,6e,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 4-(2-acetyl-4-oxoundec-1-en-1-yl)-6-propylpyridine-3-carboxylate
methyl 3-[(2r,3s,4s,8s,11s,13r,16s,17r,19r)-11-hydroxy-13,17-dimethyl-1-azahexacyclo[9.7.1.0²,¹⁶.0³,¹³.0⁴,⁸.0⁸,¹⁹]nonadecan-3-yl]propanoate
C24H37NO3 (387.27732920000005)
methyl (1'r,3r,5's,6s)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
methyl 4-[(1e)-2-acetyl-4-oxoundec-1-en-1-yl]-6-propylpyridine-3-carboxylate
(2e,4e,6e,8e,10z,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(2e,4e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
2-[(1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene)amino]-3-(4-hydroxyphenyl)propanoic acid
methyl (1r,3r,4s,10s,14s,15r,17s,18s,19r)-17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
methyl (1r,3s,4r,10s,14s,15r,17r,18s,19r)-17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
2-{[(2e,4e,6r)-1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
methyl (1's,3r,5's,6s)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
5-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-2-(2-hydroxyethyl)-7-methoxy-3,6-dimethyl-3h-isoindol-1-one
n-[(1s,2e,4e,6r,8e,10e,12s,14e,17s)-6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl]ethanimidic acid
(2s)-3-hydroxy-2-{[(2e,4e,6e,8e)-1-hydroxy-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ylidene]amino}propanoic acid
(2s,4z)-4-{[(1s,2r,4as,6r,8ar)-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-[(1r)-1-hydroxyethyl]-2h-pyrrol-3-one
n-[(1s,2e,4e,6r,8e,10e,12s,14e,17r)-6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl]ethanimidic acid
(8e,10e)-13-hydroxy-n-(1-methoxypropan-2-yl)-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
2-(12-hydroxy-12-methyltridecyl)-3-methoxy-3h-quinolin-4-one
C24H37NO3 (387.27732920000005)
13-hydroxy-n-(1-methoxypropan-2-yl)-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
methyl 3-{11-hydroxy-13,17-dimethyl-1-azahexacyclo[9.7.1.0²,¹⁶.0³,¹³.0⁴,⁸.0⁸,¹⁹]nonadecan-3-yl}propanoate
C24H37NO3 (387.27732920000005)
(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(2s)-2-{[(2e,4e,6r)-1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
2-(12-hydroxy-12-methyltridecyl)-3-methoxy-1h-quinolin-4-one
C24H37NO3 (387.27732920000005)
(2e,4e,6e,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
2,2,2-trifluoro-1-[2-methyl-3-(pentadec-7-en-1-yl)-4,5-dihydropyrrol-1-yl]ethanone
C22H36F3NO (387.27488420000003)
5-hydroxy-4-{hydroxy[1,3,6-trimethyl-2-(prop-1-en-1-yl)-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methylidene}-2-(1-hydroxyethyl)-2h-pyrrol-3-one
(1r,2s,12r,15s)-12-(2-hydroxypropan-2-yl)-7-methoxy-10,13,19-triazapentacyclo[11.7.0.0³,¹¹.0⁴,⁹.0¹⁵,¹⁹]icosa-3(11),4,6,8-tetraene-1,2-diol
C21H29N3O4 (387.21579540000005)